TOVX

PRE 14A - Theriva Biologics, Inc. (0000894158) (Filer)

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases - - Data to be presented in a poster session at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California on Monday April 20, 2026- ROCKVILLE, Md., April 17, 2026 (GLOBE NEWSWIRE) --  Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announce

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

– Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – – Combined feedback from FDA and previously from EMA enables company to finalize protocol for pivotal Phase 3 clinical trial while pursuing strategic funding opportunities ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the outcomes of a recent Type B End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug

DEF 14A - Theriva Biologics, Inc. (0000894158) (Filer)

10-K - Theriva Biologics, Inc. (0000894158) (Filer)

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

- Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales - - Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027- ROCKVILLE, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported fin

PRE 14A - Theriva Biologics, Inc. (0000894158) (Filer)

DENVER, Feb. 19, 2026 (GLOBE NEWSWIRE) -- U.S. equity markets are pointing modestly lower this Thursday morning. The focus remains on earnings season kickoff and any fresh Fed commentary, but today's headlines are dominated by transformative deals and production milestones that are lifting small- and mid-cap names. Key Movers & Catalysts Driving the Tape Interactive Strength (NASDAQ:TRNR) is the standout gainer pre-market, surging more than 40% after announcing a definitive agreement to acquire Ergatta, the game-based connected fitness pioneer. The deal boosts TRNR's 2026 pro forma revenue guidance by 50%, to more than $30 million, with Ergatta alone expected to deliver > $10 million in

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

- Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - Rasayana to assume all responsibility and costs for SYN-020 development and commercialization - ROCKVILLE, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported the out-licensing of SYN-020, to Rasayana Therapeutics, Inc., a privately-held company targeting the Gut-Organ axis biology to discover and deliver transforma

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong on Saturday, 07 February 2026 – - Preclinical data will highlight synergistic antitumor activity for the combination of topotecan and VCN-01 that may improve outcomes in refractory retinoblastoma patients with difficult-to-treat vitreous seeds - ROCKVILLE, Md. and BARCELONA, Spain, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to tre

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

4 - Theriva Biologics, Inc. (0000894158) (Issuer)

4 - Theriva Biologics, Inc. (0000894158) (Issuer)

4 - Theriva Biologics, Inc. (0000894158) (Issuer)

4 - Theriva Biologics, Inc. (0000894158) (Issuer)

DEF 14A - Theriva Biologics, Inc. (0000894158) (Filer)

8-K - Theriva Biologics, Inc. (0000894158) (Filer)

- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size, repeated dosing of VCN-01, and an adaptive design to potentially optimize trial timelines and outcomes - - Theriva to schedule an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize the design of a pivotal multinational Phase 3 clinical trial - - Theriva's cash runway until Q1 2027 supports completion of regulatory activities, protocol development, and partnering activities to support proposed pivotal trials of VCN-01 in metastatic PDAC and retinoblastoma - ROCKVILLE, Md., Dec. 29,

PRE 14A - Theriva Biologics, Inc. (0000894158) (Filer)